Stephen V. Liu
Georgetown University
H-index: 47
North America-United States
Top articles of Stephen V. Liu
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions | Dong-Wan Kim Alison M Schram Antoine Hollebecque Kazumi Nishino Teresa Macarulla | 2024/1 | |
Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions | Lung Cancer | Stephen V Liu Claas Frohn Lori Minasi Kristie Fernamberg Andrew J Klink | 2024/2/1 |
Surfaceome and cancer testis antigen profiling of lung adenocarcinoma by large-scale transcriptomic analysis | Cancer Research | Swartz Andrew Andrew Elliott George W Sledge Stephen V Liu Balazs Halmos | 2024/3/22 |
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer | Journal of Clinical Oncology | Charles M Rudin Stephen V Liu Ross A Soo Shun Lu Min Hee Hong | 2024/1/1 |
Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study | Frank Griesinger Giuseppe Curigliano Vivek Subbiah Christina S Baik Daniel SW Tan | 2024/2/1 | |
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced Non-Small Cell Lung Cancer Previously Treated With an Immune Checkpoint Inhibitor: Results From … | JTO Clinical and Research Reports | Joel W Neal Armando Santoro Maria Gonzalez-Cao Farah Louise Lim Bruno Fang | 2024/3/20 |
Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC) | Melina Elpi Marmarelis Connor B Grady Caroline McCoach Fangdi Sun Geoffrey Liu | 2023/6/1 | |
Recent Advances and Future Strategies in First-Line Treatment of ES-SCLC | Igor Gomez-Randulfe Rita Leporati Brinda Gupta Stephen Liu Raffaele Califano | 2024/1/29 | |
Real-world survival of patients treated with taxane therapy after exposure to immunotherapy and platinum-based chemotherapy for advanced non-small-cell lung cancer without … | ESMO Real World Data and Digital Oncology | SV Liu X Hu D Chirovsky W Meng A Samkari | 2024/3/1 |
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers | Nature Cancer | Maishara Muquith Magdalena Espinoza Andrew Elliott Joanne Xiu Andreas Seeber | 2024/3/25 |
Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab | Oncology and Therapy | Reyes Bernabé Stephen V Liu Amparo Sánchez-Gastaldo Miriam Alonso García | 2024/1/27 |
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade | Cancer Cell | Barzin Y Nabet Habib Hamidi Myung Chang Lee Romain Banchereau Stefanie Morris | 2024/2/9 |
Characterization of PDLIM2 in non-small cell lung cancer | Cancer Research | Karam Ashouri Harris Krause Andrew Elliott Stephen V Liu Patrick C Ma | 2024/3/22 |
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer | medRxiv | Connor B Grady Wei-Ting Hwang Joshua E Reuss Wade Iams Amanda Cass | 2024 |
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non–Small … | JCO Precision Oncology | Abdul Rafeh Naqash Charalampos S Floudas Etan Aber Asaf Maoz Amin H Nassar | 2024/2 |
Tissue-specific thresholds and microenvironment correlates of tumor mutation burden associated with immunotherapy benefit and prognosis in microsatellite stable cancers | Cancer Research | Maishara Muquith Magdalena Espinoza Andrew Elliott Joanne Xiu Andreas Seeber | 2024/3/22 |
Validation of a whole exome/whole transcriptome liquid biopsy assay with correction for clonal hematopoiesis. | Nieves Perdigones Borderias Jim Abraham Milan Radovich Matthew James Oberley Jeffrey Swensen | 2023/6/1 | |
Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint … | Matthew James Hadfield Nishant Gandhi Alex Patrick Farrell Christopher G Azzoli Ari M Vanderwalde | 2023/6/1 | |
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer | Frontiers in Oncology | Robert Hsu Denaly Chen Bing Xia Rebecca Feldman Wendy Cozen | 2023/8/28 |
Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes. | Hina Khan Julia Judd Joanne Xiu Asad Ullah Girindra Raval | 2023/6/1 |
